The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd Edition. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Epidemiology and comorbidity of headache. The impact of migraine on quality of life in the general population: the GEM study. Migraine–current understanding and treatment. The emergence of new treatment targets and therapies illustrates the bright future for migraine management. Several neuromodulation modalities have been approved for acute and/or preventive migraine treatment. Intramuscular onabotulinumtoxinA may be helpful in chronic migraine (migraine on ≥15 days per month) and monoclonal antibodies targeting CGRP or its receptor, as well as two gepants, have proven effective and well tolerated for the preventive treatment of migraine. CGRP receptor antagonists (gepants) and lasmiditan, a selective 5HT1 F receptor agonist, have emerged as effective acute treatments. Because of cardiovascular safety concerns, unreliable efficacy and tolerability issues, use of ergots to abort attacks has nearly vanished in most countries. Management includes analgesics or NSAIDs for mild attacks, and, for moderate or severe attacks, triptans or 5HT 1B/1D receptor agonists. Despite earlier beliefs, vasodilation is only a secondary phenomenon and vasoconstriction is not essential for antimigraine efficacy. Spreading depolarization probably causes aura and possibly also triggers trigeminal sensory activation, the underlying mechanism for the headache. Depression, epilepsy, stroke and myocardial infarction are comorbid diseases. The aetiology is multifactorial with rare monogenic variants. Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.Migraine is a common, chronic, disorder that is typically characterized by recurrent disabling attacks of headache and accompanying symptoms, including aura. PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke. Women with onset of PMVA within the previous year had 6.9-fold higher adjusted odds of stroke (95% CI, 2.3 to 21.2) compared to women with no history of migraine. Women with PMVA who were current cigarette smokers and current users of oral contraceptives had 7.0-fold higher odds of stroke (95% CI, 1.3 to 22.8) than did women with PMVA who were nonsmokers and non-oral contraceptive users. Women with PMVA had 1.5 greater odds of ischemic stroke (95% CI, 1.1 to 2.0) the risk was highest in those with no history of hypertension, diabetes, or myocardial infarction compared to women with no migraine. Based on their responses to a questionnaire on headache symptoms, subjects were classified as having no migraine, probable migraine without visual aura, or probable migraine with visual aura (PMVA). Using data from a population-based, case-control study, we studied 386 women ages 15 to 49 years with first ischemic stroke and 614 age- and ethnicity-matched controls. We assessed the association of probable migraine with and without visual aura with ischemic stroke within subgroups defined by stroke subtype, vascular territory, probable migraine characteristics, and other clinical features. Migraine with aura is associated with ischemic stroke, but few studies have investigated the clinical and anatomic features of this association.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |